Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > A Message To Board Director - Dr. Mark Williams, PhD, MBA

<< Previous

Bullboard Posts

Next >>

Comment by C10H12N2on Mar 30, 2023 7:11pm

104 Views

Post# 35370639

RE:RE:RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA

Dunno. I report. You decide. What I'd surmise at first glance is Williams likely held back what he'd consider his best repurposed drug candidate for himself. Of all the repurposed drug candidates Algernon bought from him from Nash Pharmaceuticals only one drug "Ifenprodil" ever advanced to a clinical trial.What that tells me is the remaining pipeline is worthless. Once again, I report. You decide.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments